Photocure ASA ((PHCUF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The Blue Light Cystoscopy With Cysview® Registry study, officially titled the same, aims to collect comprehensive data on the use of Blue Light Cystoscopy with Cysview (BLCC) in urologists’ practices. This observational study is significant as it seeks to enhance understanding of BLCC’s role in managing bladder cancer, potentially improving patient outcomes.
The study tests two interventions: the drug Hexaminolevulinate hydrochloride (HCL), used for bladder instillation, and the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system, employed during the cystoscopy procedure. These interventions aim to improve the detection and management of bladder cancer.
This observational study follows a case-only model with a prospective time perspective. It does not involve random allocation or masking, focusing instead on real-world application and outcomes of the BLCC procedure.
The study began on January 6, 2016, with its primary completion and estimated overall completion yet to be announced. The latest update was submitted on August 18, 2025, indicating ongoing progress and data collection.
The continuation of this study could positively influence Photocure ASA’s stock performance by reinforcing its commitment to advancing bladder cancer treatment. As the study progresses, investor sentiment may become more optimistic, especially if interim results show promising outcomes compared to competitors in the urology field.
The Blue Light Cystoscopy With Cysview® Registry study is currently recruiting, with further details available on the ClinicalTrials portal.